207 related articles for article (PubMed ID: 20542323)
1. Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis.
Conus S; Straumann A; Bettler E; Simon HU
J Allergy Clin Immunol; 2010 Jul; 126(1):175-7. PubMed ID: 20542323
[No Abstract] [Full Text] [Related]
2. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.
Stein ML; Collins MH; Villanueva JM; Kushner JP; Putnam PE; Buckmeier BK; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2006 Dec; 118(6):1312-9. PubMed ID: 17157662
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis.
Conus S; Straumann A; Simon HU
J Allergy Clin Immunol; 2009 Jan; 123(1):269; author reply 269-70. PubMed ID: 18951621
[No Abstract] [Full Text] [Related]
4. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
Straumann A; Conus S; Grzonka P; Kita H; Kephart G; Bussmann C; Beglinger C; Smith DA; Patel J; Byrne M; Simon HU
Gut; 2010 Jan; 59(1):21-30. PubMed ID: 19828470
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
8. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis.
Otani IM; Anilkumar AA; Newbury RO; Bhagat M; Beppu LY; Dohil R; Broide DH; Aceves SS
J Allergy Clin Immunol; 2013 Jun; 131(6):1576-82. PubMed ID: 23623266
[TBL] [Abstract][Full Text] [Related]
9. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response.
Straumann A; Bauer M; Fischer B; Blaser K; Simon HU
J Allergy Clin Immunol; 2001 Dec; 108(6):954-61. PubMed ID: 11742273
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.
Konikoff MR; Noel RJ; Blanchard C; Kirby C; Jameson SC; Buckmeier BK; Akers R; Cohen MB; Collins MH; Assa'ad AH; Aceves SS; Putnam PE; Rothenberg ME
Gastroenterology; 2006 Nov; 131(5):1381-91. PubMed ID: 17101314
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic characterization and quantification of the epithelial inflammatory infiltrate in eosinophilic esophagitis through stereology: an analysis of the cellular mechanisms of the disease and the immunologic capacity of the esophagus.
Lucendo AJ; Navarro M; Comas C; Pascual JM; Burgos E; Santamaría L; Larrauri J
Am J Surg Pathol; 2007 Apr; 31(4):598-606. PubMed ID: 17414108
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis.
Straumann A; Bussmann C; Conus S; Beglinger C; Simon HU
J Allergy Clin Immunol; 2008 Aug; 122(2):425-7. PubMed ID: 18678345
[No Abstract] [Full Text] [Related]
13. Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis.
Lucendo AJ; De Rezende L; Comas C; Caballero T; Bellón T
Am J Gastroenterol; 2008 Sep; 103(9):2184-93. PubMed ID: 18844613
[TBL] [Abstract][Full Text] [Related]
14. Reslizumab for pediatric eosinophilic esophagitis.
Walsh GM
Immunotherapy; 2010 Jul; 2(4):461-5. PubMed ID: 20636000
[TBL] [Abstract][Full Text] [Related]
15. Deal watch: Anti-IL-5 antibody attracts Cephalon to agree option for Ception acquisition.
Nat Rev Drug Discov; 2009 Mar; 8(3):185. PubMed ID: 19247299
[No Abstract] [Full Text] [Related]
16. Psoriasis patients have highly increased numbers of tryptase-positive mast cells in the duodenal stroma.
Michaëlsson G; Kraaz W; Hagforsen E; Pihl-Lundin I; Lööf L
Br J Dermatol; 1997 Jun; 136(6):866-70. PubMed ID: 9217818
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.
Stein ML; Villanueva JM; Buckmeier BK; Yamada Y; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2008 Jun; 121(6):1473-83, 1483.e1-4. PubMed ID: 18410960
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of esophageal rings in eosinophilic esophagitis.
Mann NS; Leung JW
Med Hypotheses; 2005; 64(3):520-3. PubMed ID: 15617859
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.
Smith DA; Minthorn EA; Beerahee M
Clin Pharmacokinet; 2011 Apr; 50(4):215-27. PubMed ID: 21348536
[TBL] [Abstract][Full Text] [Related]
20. The role of mast cells in eosinophilic esophagitis.
Lucendo AJ; Bellón T; Lucendo B
Pediatr Allergy Immunol; 2009 Sep; 20(6):512-8. PubMed ID: 18681944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
